Erythema Multiforme; Red dots on torso; Itching; diarrhea; abdominal cramping; redness; itchy eyes; runny nose; feeling hot; tingling sensation; Hypersensitivity reaction; Hard to touch; Itchiness; Pain at injection site; nausea; chills; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of ERYTHEMA MULTIFORME (Erythema Multiforme) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 017c21a) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Vomiting on 01-May-2002. Previously administered products included for an unreported indication: Z-PAK.    On 17-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-May-2021, the patient experienced ERYTHEMA MULTIFORME (Erythema Multiforme) (seriousness criterion medically significant), RASH ERYTHEMATOUS (Red dots on torso), PRURITUS (Itching), DIARRHOEA (diarrhea), ABDOMINAL PAIN (abdominal cramping), ERYTHEMA (redness), EYE PRURITUS (itchy eyes), RHINORRHOEA (runny nose), FEELING HOT (feeling hot), PARAESTHESIA (tingling sensation), HYPERSENSITIVITY (Hypersensitivity reaction), VACCINATION SITE INDURATION (Hard to touch), VACCINATION SITE PRURITUS (Itchiness), VACCINATION SITE PAIN (Pain at injection site), NAUSEA (nausea) and CHILLS (chills). The patient was treated with LORATADINE, PSEUDOEPHEDRINE HYDROCHLORIDE (BENADRYL 24 D) for Adverse reaction, at a dose of 1 dosage form. On 27-Jun-2021, ERYTHEMA MULTIFORME (Erythema Multiforme), PRURITUS (Itching), DIARRHOEA (diarrhea), ABDOMINAL PAIN (abdominal cramping), ERYTHEMA (redness), EYE PRURITUS (itchy eyes), RHINORRHOEA (runny nose), FEELING HOT (feeling hot), PARAESTHESIA (tingling sensation), HYPERSENSITIVITY (Hypersensitivity reaction), NAUSEA (nausea) and CHILLS (chills) had resolved. At the time of the report, RASH ERYTHEMATOUS (Red dots on torso), VACCINATION SITE INDURATION (Hard to touch), VACCINATION SITE PRURITUS (Itchiness) and VACCINATION SITE PAIN (Pain at injection site) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was withdrawn on an unknown date.       The concomitant medications were not reported.  It was reported that the patient seek medical care at Doctor's office  and date of hospitalization was reported as 27-MAY-2021.  It was reported that the adverse events are most likely caused by mRNA-1273.  The consumer mentioned that she contacted an ER doctor identified the rash she developed as Erythema Multiforme. She mentioned that she asked if she should get the second dose and the ER doctor talked with a few other doctors and a derm and they all agreed that she should not get anymore shots.  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   Most recent FOLLOW-UP information incorporated above includes: On 28-Jul-2021: Event added, contact info updated; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.